Navigation Links
Collaboration and innovation win CWRU School of Medicine grant to study gastric cancer

CLEVELAND February 7, 2013 - The Case Western Reserve University School of Medicine has received a $220,000 grant from the DeGregorio Family Foundation to study gastric cancers, which remain among the most deadly forms of disease.

The two-year grant from the foundation, which focuses on stomach and esophageal cancer research and education, will support studies aimed at identifying and developing more effective treatments for gastric and esophageal malignancies.

The grant focuses on interleukin-33 (IL-33), a novel mediator that causes inflammation. That inflammation in turn may be involved in the early events leading to development of gastrointestinal cancers, including gastric cancer. IL-33 is the newest member of the IL-1 family of cytokines, which are specific molecules involved in various disease processes, such as inflammation, autoimmunity, and cancer. Cytokines are produced by many different types of cells and deliver signals that allow cells to communicate with each other.

"We are grateful to the DeGregorio Family Foundation for having chosen to support our project this year and for bringing attention to upper GI malignancies," said Theresa Pizarro, PhD, associate professor of Pathology and Medicine, Case Western Reserve University School of Medicine, and the study's principal investigator. "Using a multi-disciplinary approach, we are hopeful that this research will allow us to study novel pathways that will uncover the potential sequence of events that occur from inflammation in the stomach to gastric cancer, and to generate more specific and targeted treatment modalities for this devastating disease, for which there is currently no cure. The DeGregorio funds will be critical for this mission and to further expand our research program in this important area of investigation."

Dr. Pizarro's expertise is in cytokine biology, focused on the characterization and function of IL-1 family members, and the role they play in inflammation and gastrointestinal diseases.

Li Li, MD, PhD, associate professor of Family Medicine, Epidemiology & Biostatistics and associate director for Prevention Research, Case Comprehensive Cancer Center, Case Western Reserve University, is the co-investigator. Wei Xin, MD, PhD, assistant professor of Pathology, is the collaborator.

Lynn DeGregorio, president of the DeGregorio Family Foundation, based in New York City, said, "The foundation has always sought to fund research that is innovative and will be a catalyst to collaboration. The application from the Case Western Reserve University School of Medicine will increase the depth and breadth of research into these malignancies, and so we were excited to be able to make this award possible."

Pizarro's funded proposal, entitled, "Role of the novel IL-1 family member, IL-33, in the gastritis-metaplasia-carcinoma sequence," was the only proposal of 24 international applicants selected for funding in the third annual DeGregorio Foundation Award for Cancers.

Stomach cancer, which caused over 10,000 deaths in the United States in 2012 according to the National Cancer Institute, is the second-most common cause of cancer-related mortality, behind only lung cancer. And less than 10 percent of patients diagnosed with esophageal cancer will survive longer than 5 years.

Today, stomach and esophageal cancers are treated as orphan diseases despite their prevalence and deadliness. Together, more than 1.3 million people will be diagnosed with an upper GI malignancy annually, according to NCI.


Contact: Christine A. Somosi
Case Western Reserve University

Related medicine news :

1. Damaka introduces Xabr™, a Native Mobile Video & Collaboration Client for Cisco® Jabber®, CallManager, and TelePresence
2. ASH international clinical collaboration replicates high cure rate of APL in developing countries
3. Kentucky receives top honors in nations capital for health IT collaboration
4. Merck and Regenstrief Institute establish evidence-based care collaboration
5. Mass. Eye and Ear, Joslin Diabetes announce collaboration in eye care
6. New collaboration to develop treatments for liver disease
7. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
8. Treating the whole person with autism sets direction for parent-clinician collaboration
9. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
10. Making Sickness Old Fashioned, That's Called Wellness - An Innovation by Perfect Wellness
11. Co-Founder of Omega3 Innovations Says Today’s Fish Oil Industry is on the Wrong Track, Sets Up Blog to Help Consumers Understand Why
Post Your Comments:
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, ... for the Narconon network, announced the release of a new cutting edge recovery program ... organization has been working with drug- and alcohol-addicted individuals with the purpose to free ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary ... Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 as ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ) today announced that ... York State Attorney General,s Office to end the ... statutes with the Attorney General over the decision of Forest ... selling the now generic version of memantine immediate release tablets.  ... released its counterclaims against New York , ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 2015 --> ... devices was valued at $11,171.1 million in 2014, and ... 5.7% during 2015 - 2022. The global market is ... of diabetes. In addition, the increase in obese population ... to the growth of the market. Furthermore, technological advancements ...
Breaking Medicine Technology: